World Health Organization Sounds Concern Over Acute Shortage of Weight-Loss Jabs

Under 10% of people that would benefit from GLP-1 drugs including Wegovy can access them, warns the World Health Organization as it publishes its initial recommendations on the therapies.

With over a billion people worldwide currently living with obesity, it is urging increased and just availability to these injectable treatments.

Per projections, in excess of 2,000,000,000 could be obese by 2030 unless action is taken.

"The new guidance acknowledges that obesity is a long-term condition that can be managed with comprehensive and continuous care," stated its chief Tedros Adhanom Ghebreyesus.

Substantial prices, limited production capacity, and supply-chain constraints are significant obstacles to broad availability to the jabs that can aid individuals in losing substantial weight, notes the organization.

Weight-Loss Drug Supply Crisis

Even under the present most optimistic scenario, the manufacturing of GLP-1 therapies could only cover about 100 million people – fewer than 10% of the global need, as stated by the health organization.

The guideline urges countries and companies to increase availability, through approaches like patent sharing.

A patent on the active ingredient – the main ingredient of a leading brand – is scheduled to end in a number of countries in 2026.

The Way Weight-Loss Injections Function

These medications replicate a biological compound to reduce digestion speed, reduce hunger and enhance satiety so individuals reduce food intake.

Individuals typically see weight reduction after several weeks of starting on the regular doses.

Research points to users may regain a significant portion a year later of stopping the treatment, because their normal food cravings come back.

Being above a healthy weight elevates your risk for contracting health problems, such as diabetes, heart disease, brain attack, and some cancers.

Excess weight affects individuals in every country and was linked to 3.7 million fatalities worldwide in 2024, per the WHO.